key: cord-0781468-go5rdch8
authors: nan
title: Collaborative Group of the Americas on Inherited Gastrointestinal Cancers (CGA-IGC) Annual Virtual Meeting, November 13–15, 2021
date: 2022-04-02
journal: Fam Cancer
DOI: 10.1007/s10689-021-00284-8
sha: 89d7c7d0a706cfea1d2dbc812a346a18d890d3ae
doc_id: 781468
cord_uid: go5rdch8

nan

Background Biallelic pathogenic germline variants in MSH3 have been described in a small number of individuals with adenomatous oligopolyposis of the colorectum, with polyps demonstrating MSI at dinucleotide repeats and elevated microsatellite alterations at selected tetranucleotide repeats (EMAST). MSH3 is thus thought to be an autosomal recessive cause of polyposis and colorectal cancer (CRC) susceptibility, though there is no known risk/phenotype currently associated with monoallelic/heterozygous germline variants. Here, we present a case of young-onset MSI-high colon cancer developing shortly after a normal colonoscopy, potentially caused by a monoallelic germline MSH3 variant. Case presentation The patient is an otherwise healthy female who began colonoscopic surveillance at age 25, due to the family history of CRC ( Figure) . Colonoscopies at ages 25, 30, and 35 were normal, and follow-up was planned for age 40. At age 39, she was found to have a right-sided colon mass after presenting with abdominal pain and anemia. Right hemicolectomy revealed moderately-differentiated pT3N0 adenocarcinoma with intact IHC for MLH1/MSH2/MSH6/PMS2. Somatic sequencing determined the cancer to be MSI-high with 69.2 mutations/ Mb with a predicted loss-of-function MSH6 c.3253_3254insC (p.Phe1088Leufs*5) variant and other missense MMR gene variants without predicted pathogenicity (MSH3 not evaluated on this assay). Germline testing identified a heterozygous ''likely pathogenic'' c.1764-1G [ A MSH3 variant, expected to disrupt the intron 12 acceptor splice site; no other MMR gene variants were identified. Subsequent multigene germline testing on her father identified homozygous carriage of the c.1764-1G [ A MSH3 variant. He had prior right-sided colon cancer at age 50 as well as colonic adeno-matous oligopolyposis (exact number of polyps unknown) and prior duodenal adenomas. Discussion The MSI-high findings and short-interval development of this cancer despite early-onset colonoscopic surveillance suggests that the heterozygous MSH3 germline variant may have played a causative role in carcinogenesis. Additional analysis is underway on the index patient's colon cancer -including MSH3 IHC, MSH3 sequencing, EMAST evaluation, RNAseq, and whole exome sequencing -which could further clarify the etiologic role of this monoallelic germline MSH3 variant and the biology of such malignancies. This case highlights the need for further data on the clinical significance and possible phenotype of monoallelic germline MSH3 variants.

Background Obtaining a family history at the time of colonoscopy allows gastroenterologists to identify patients who would benefit from genetic screening. However, in practice, obtaining and applying this information to patient recommendations is observed to be inconsistent. Therefore, we sought to determine the baseline rate of family history documentation and compliance with appropriate referral to a hereditary cancer clinic among endoscopists in our own institution. Methods Endoscopy reports were retrospectively reviewed for patients 18-89 years old who underwent a screening or surveillance colonoscopy between 12/2019-12/2020 at a tertiary care center. Data collected included demographics, family history documentation, procedural details and determination of criteria fulfillment for referral to hereditary cancer clinic. The data was stratified into two groups: physicians with designated focus in hereditary colon cancer (Hereditary Focus Group) and remainder of gastroenterology faculty (General Group). Results 1222 consecutive colonoscopy reports were reviewed. 334 of the procedures were performed by the hereditary focus group and 887 were performed by the general group. The hereditary focus group was more likely to document family history at the time of colonoscopy (78.1% vs 68.3%, p = 0.001). Among those procedure reports where family history was not documented, the majority were surveillance colonoscopies in both hereditary focus group and general group (89.0% vs 82.6%). In the hereditary focus group 5.1% (n = 17) of patients met criteria for referral to hereditary cancer clinic, 42.1% (n = 7) were not referred despite meeting institutional criteria. In the general group, 2.4% (n = 21) of patients met criteria for referral and 61.9% (n = 13) were not referred despite meeting institutional criteria. Conclusion Family history assessment at time of colonoscopy plays a critical role in allowing identification of high-risk individuals with genetic disposition for development of colorectal cancer. In our institution, the hereditary focus group had a higher rate of family history documentation compared to remainder of general faculty. However, both groups had substantial missed opportunities for referral to hereditary cancer clinic. Heightened awareness of proper referral criteria and standardization of family history documentation in colonoscopy reports may be potential modalities to achieve improvements in both these areas.

Diffuse gastric cancer in a family with a germline, pathogenic ATM variant Travis Washburn, MS, CGC 1 , Jacquelyn Roberson, MD, FACMG 1 1 Division of Medical Genetics, Henry Ford Health System, 3031 W. Grand Blvd. Detroit, MI 48,202, USA Background Heterozygous, germline ATM pathogenic variants (PV) are associated with hereditary breast cancer. Literature supports there is likely an increased risk of pancreatic cancer and possibly other cancers including gastric cancer (1) . Several studies examining individuals with diffuse gastric cancer identified heterozygous, germline ATM PV in their cohort (2, 3) . We report a case of a family with only diffuse gastric cancer that segregates with the ATM PV. Case Presentation A 38-year-old male presented with a history of postprandial gastric pain for three months and three weeks of vomiting. EGD showed diffuse ulceration in the entire antrum and prepyloric region and an ulcerated mass-like lesion in the antrum. A biopsy noted poorly differentiated carcinoma. CT scan showed distended stomach with wall thickening involving antrum. He had a gastrectomy with Bilroth II anastomosis with biopsy of mesenteric lymph node and peritoneal nodule. Final pathology showed adenocarcinoma, diffuse type. Paired germline/somatic tumor testing identified a germline ATM PV (p.K750K), which is known to cause abnormal splicing. The patient completed 10 cycles of mFOLFOX7. He presented to Medical Genetics given his early-onset diffuse gastric cancer and family history of a paternal uncle with diffuse gastric cancer who was also previously seen in Medical Genetics. This paternal uncle was heterozygous for the same ATM PV. The family history was not significant for any other cancers (Fig. 1) . Germline testing for the patient was performed using a 37-gene panel test (including CDH1 and CTNNA1) that included RNA analysis and confirmed the heterozygous, ATM PV found in the tumor. All other genes analyzed were negative. Discussion This case illustrates that an ATM PV may increase the risk of diffuse gastric cancer which recent studies have also suggested [1] [2] [3] [4] . Confirming an association between an ATM PV and an increased risk of diffuse gastric cancer will have important, future screening implications. We cannot exclude the possibility that there may be another underlying genetic mechanism that is causing diffuse gastric cancer in this family beyond the ATM PV. Additional research will be helpful in further defining this cancer risk. Background Southern California has a high proportion of Hispanic residents, representing 34-49% of the Orange/Los Angeles County areas. The regional Centers for Clinical Genetics and Genomics in Southern California provide population screening, risk assessment, and genetic testing programs to identify and counsel carriers of pathogenic variants. The CDKN2A: c.146 T [ C (p.I49T) variant is characterized by most laboratories as a likely pathogenic, moderaterisk variant, and is found in 0.44% of Hispanic/Latin American individuals. Given the prevalence of this variant within an underserved population and absence of penetrance estimates and management guidelines, the objective of this study was to report findings of personal and family history and screening compliance. Methods IRB exemption was granted to perform a retrospective chart review and regional data sharing to collate individuals and families found to carry the CDKN2A: c.146 T [ C (p.I49T) variant. Information collected included: ancestry, age, personal and family history, genetic test results, management recommendations, and screening compliance. Results We identified 33 carriers of the p.I49T variant, 30 of whom (90.9%) reported full/partial Mexican ancestry. Two carriers of an additional, high-risk, variant were excluded. Of the 31 remaining, 3 (9.7%) had pancreatic cancer, 1 (3.2%) had melanoma, 4 (12.9%) reported family history of pancreatic cancer, 3 (9.7%) reported family history of melanoma, and 25 (80.6%) reported no family history of pancreatic cancer or melanoma. The average age was 47.3 (range 21-79) and sex ratio was 90.9% female to 9.1% male. Of the 22 (84.6%) identified greater than 6 months ago, 21 were advised to initiate screening, and 14 of 21 (66.7%) had not completed any melanoma or pancreas screening. Due to increasing population screening programs, 7 (21.2%) were identified within the last 6 months. (See Table 1 ). Conclusions The p.I49T carriers in this study exhibited reduced screening compliance compared to past studies. Ethnic health disparities, limited variant-specific information, particularly for variants identified in non-white populations, and the absence of personal or family history of associated cancers likely contribute to reduced compliance. Further studies are needed to provide accurate risk assessment and management information, to increase male carrier identification, and to improve meaningful communication and screening compliance.

Wnt pathway components in the predisposition to serrated polyposis Background Peutz-Jeghers syndrome (PJS) is a cancer predisposition condition associated with transient mucocutaneous hyperpigmentation and an increased risk for benign and malignant tumors of the gastrointestinal tract, breast, and reproductive organs due to mutations in STK11. Mosaicism is a phenomenon resulting from development of a genetic mutation in an embryo and leading to the presence of multiple cell lines. There are limited case reports of mosaic PJS. Case presentation A 35-year-old Ashkenazi Jewish (AKJ) female with a history of three Peutz-Jeghers type polyps of the small bowel and one ''lip freckle'' which appeared in childhood and faded in adulthood. She denied any family history of cancer or other clinical features of PJS. At her pre-test genetic counseling consultation, she met clinical diagnostic criteria for PJS. Genetic testing identified a low-level mosaic pathogenic mutation in STK11 and two AKJ founder mutations in FANCC and APC. Discussion This case represents an important minority of persons with a clinical diagnosis of PJS in the context of an apparently de novo, mosaic mutation in STK11. This patient's STK11 mutation was found at the lowest level detectable by the laboratory and it was reported that it likely would have been missed had a thorough personal and family history not been provided to the laboratory. This highlights the vitality of provision of detailed medical history information at the time of test requisition and the contribution of genetic counselors as members of a medical team to meeting this need. Further, this patient was aware prior to her initial consultation that persons of AKJ ancestry have a higher frequency of certain genetic conditions. However, this patient demonstrated significant difficulty in understanding the distinction between the general concept of increased frequency of certain genetic conditions in persons of AKJ ancestry, the AKJ founder mutations for which she was identified as a carrier, and her mosaic STK11 mutation which is unrelated to her ancestry. This case illustrates the need for comprehensive pre-and post-test genetic counseling to review complex genetic test results in the context of personal and family history and appropriately manage medical care based on this information.

Background The characteristics and progression of duodenal disease in MAP are poorly understood. This prospective study of duodenal disease in patients with MAP addresses these issues with the aim of informing future upper gastrointestinal surveillance recommendations. Methods This is a long-term prospective cohort study that collates standardised demographic and genotype information, details of endoscopic surveillance findings and therapy from collaborating centres.

We recently published the initial findings in 394 patients with genetically confirmed MAP who had undergone one or more upper GI endoscopies (Gastroenterology 2021 Feb;160(3):952-954). 57/394 MAP patients had duodenal disease at index endoscopy (14.5%) at a median age of 51 years (range; 37-81): this was Spigelman stage I in 35 patients (61.4%), stage II in 11 (19.3%), stage III in 10 (17.5%) and stage IV in 1 patient (1.8%). The risk of duodenal polyposis at index endoscopy in MAP depended on genotype, with Y179C homozygotes at highest risk. 202 patients had follow up endoscopies (1463 follow up years). Stage IV disease remained uncommon (1.5% at a median age of 55 years) but three patients (1.4%) developed duodenal cancer, all apparently without prior stage IV disease. Solitary polyps, high grade dysplasia in small adenomas (\ 10 mm) and a lack of ampullary disease may also be characteristic of duodenal disease in MAP. Conclusions Initial cross-sectional analysis suggests duodenal disease in MAP progresses differently to FAP. A better understanding of duodenal disease progression in MAP requires the study of more patients, information on procedure quality, and longer prospective follow up. Our study may enable identification of better markers of disease progression risk and clarify whether and how guidance on surveillance and intervention should be revised. We invite new collaborators to join the group to address these challenges.

Background Universal tumor screening (UTS) for Lynch syndrome (LS) on colorectal cancer (CRC) can be performed on diagnostic colonoscopy biopsies or resected surgical specimens. An advantage of UTS on biopsies is the chance to provide preoperative genetic counseling/testing (GC/T) and make a diagnosis so those with LS can make informed surgical decisions regarding extent of resection. We evaluated the utilization of UTS on biopsy, the percentage of patients with deficient mismatch repair (dMMR) who underwent GC/T preoperatively, and whether surgical decision-making was impacted. Methods On 1/01/2017, we changed our UTS process to include mismatch repair (MMR) immunohistochemical staining (IHC) on CRC biopsies rather than resections whenever possible and conducted internal review from 1/01/2017-2/26/2021. Electronic medical records were reviewed for dMMR cases. Results 1,144 CRC patients had UTS using MMR IHC. 559 (48.9%) were performed on biopsies, 585 (51.1%) on resections. The main reason MMR IHC was not performed on a biopsy was it occurring outside our health system. Among 1,144 CRCs, 58 (5%) were dMMR and did not have MLH1 promoter hypermethylation when indicated. Nearly half (28/58; 48.3%) of dMMR cases were diagnosed on biopsy. Of those 28, 14 (50%) underwent GC/T at some point, 7 (25%) had GT results prior to surgery (3 already knew they had LS). Of the 6 patients who underwent surgery thus far, 5 had the LS diagnosis included in preoperative decision-making; three elected a more extensive surgery after a risk/benefit discussion with their surgeon. Overall, 5/28 (17.9%) dMMR patients identified on biopsy made an informed surgical decision based on their diagnosis of LS.

Conclusions When applied, UTS on biopsy was effective at increasing the ability to allow for LS patients to have informed surgical decision making. Many challenges remain in using biopsies for LS screening to help inform surgical procedure. To fully see the impact, uptake of this change would also need to occur at referring hospitals and there is room for improvement at our institution including patient follow-up and coordination of pre-surgery genetics consultations.

Background Mosaic mutations in the APC gene have been identified as a common cause (25%) for unexplained polyposis in patients with [ 20 adenomas. The frequency of APC mosaicism remains unknown in milder phenotypes. Methods To test for APC mosaicism, we analyzed the APC gene in multiple lesions of patients with unexplained colonic polyposis using Next Generation Sequencing. Additionally, patients with milder phenotypes, e.g.

[ 20 adenomas at age [ 70, were included. Results The mosaicism detection rate was 11% (29/271) in the entire cohort, 4.5% in patients with \ 10 adenomas (2/44) and 7.4% in those with 10-20 adenomas (9/122). Stratified for age, 2.5% (1/40) of patients aged [ 70 showed with a mosaicism. Besides these ''true'' mosaicism cases, 23% (61/271) of patients showed a so-called hybrid mosaicism, where multiple, but not all lesions share an identical variant. Interestingly, 39% (24/61) of hybrids have a specific APC splice variant c.835-8A [ G in multiple lesions. Together with other recurring APC variants, this variant was compatible with the recently described mutational signature caused by colibactin, a compound produced by pks ? E.coli. The possible influence of colibactin needs further exploration. Therefore, we are now performing additional analyses like Whole Genome Sequencing. Conclusions Our results indicate that APC mosaicism also plays a role in milder polyposis phenotypes. Furthermore, a substantial proportion of our cohort had a hybrid mosaicism of which the clinical consequences are not yet clear. In some patients, the presence of pks ? E.coli might be the explanation for the development of polyps.

Introduction Currently published data on colon neoplasia detection rates in Lynch syndrome is distorted by the inclusion of patients with previous neoplasia and multiple past procedures. Our aim was to assess the results of first ever colonoscopy performed on patients with Lynch syndrome. Methods A retrospective review of patients followed in the Hereditary and High-Risk GI Clinic from 8.2014 through 12.2020 was performed. Inclusion criteria included a pathogenic/likely pathogenic variant in a mismatch repair gene with a subsequent first ever colonoscopy performed at our center. All colonoscopies were performed by a single endoscopist (PPS). Standard definitions for advanced adenomas and sessile serrated adenomas (SSA) were utilized. Exclusion criteria included previous colonoscopy or multiple hereditary cancer syndromes. Comparisons were done by Fisher's exact test. Results There were 73 patients that met criteria, with the majority of patients having variants in MSH6 (31, 42.5%) and PMS2 (23, 31.5%) with MSH2 (13, 17.8%) and MLH1 (6, 8.2%) less frequent. Further demographic details are available in Table 1 . The median age at first colonoscopy was 35 (IQR 29.5-45.5). The mean Boston bowel prep score was 8.4 and the mean withdrawal time on procedures without intervention was 11.3 min. There were 33 patients (45.2%) with any adenoma or SSA on first colonoscopy, including 25 (34.2%) with adenoma and 12 (16.4%) with SSA. Colorectal cancer was found in 2 (2.7%), with advanced adenomas (10, 13.7%) and advanced SSA (7, 9. 6%) commonly identified ( Table 1 ). The adenoma detection rate (ADR) was significantly higher in those over 50 years of age (p = 0.04, Figs. 1, 2) and in men (p = 0.04). ADR was similar across mismatch repair genes (p = 0.64). Discussion The high detection rate of colorectal neoplasia and especially advanced neoplasia in Lynch syndrome patients undergoing first colonoscopy highlights the importance of prompt cascade testing to allow for early initiation of colonoscopy. Our results show that ADRs higher than previously published rates are achievable across mismatch repair genes and ages. However, higher ADR targets in patients over age 50 and in men should be considered as colonoscopy quality metrics are established for Lynch syndrome. Abdominal desmoid disease usually follows total proctocolectomy with ileal pouch anal anastomosis (TPC/IPAA) or total abdominal colectomy with ileorectal anastomosis (TAC/IRA). Sex, extra-intestinal manifestations, and a 3' mutation location have been identified as risk factors, but surgical risk factors are poorly understood. We hypothesize that pouch construction creates a higher risk of desmoid formation due to increased stretch of the small bowel mesentery. This study aims to investigate the surgical risk factors for desmoid formation.

Methods A single-institution, prospectively-maintained, hereditary colorectal cancer registry was queried for patients with a diagnosis of FAP who underwent either IRA or IPAA between the years 1995 and 2015. Patients who were referred to the registry following index surgery performed elsewhere were excluded, as were patients with desmoid disease diagnosed prior to colon resection. Post-operative development of symptomatic desmoid disease served as the primary endpoint. This was defined by any desmoid disease diagnosed on investigation of patient symptoms of any severity, excluding only diagnoses made purely incidentally. Demographics, presence of extraintestinal manifestations, genotype, family history of desmoid disease, and surgical details were included in analysis. Univariable and multivariable analyses were conducted to determine risk factors.

Results 345 patients met inclusion criteria. 172 (49%) patients underwent proctocolectomy/ileoanal pouch, while 173 (51%) underwent total colectomy/ileorectal anastomosis. Overall, 100 (28.9%) developed symptomatic desmoids following surgery. On univariable analysis open surgery and pouch surgery were associated with desmoid development, along with extracolonic manifestations, family history of desmoids, mutation location, and high desmoid risk score. On multivarible analysis, proctocolectomy with pouch was most strongly associated with desmoid disease (p \ 0.01, OR 6.49; Table 1 ). Other associations with desmoid formation were family history of desmoid disease and desmoid risk factor score.

Conclusions Polyposis patients who underwent total proctocolectomy with pouch by any approach had significantly greater risk of developing desmoid disease than total colectomy with ileorectal anastomosis, even when accounting for other risk factors (Table 3) . There is ample literature to support increased risk of adenoma formation in CYAC but frank polyposis with tens and hundreds of polyps and their natural history is not well studied. Case presentation Here we present an interesting patient who was incidentally diagnosed with therapy associated polyposis. This is a 43 year old female who was diagnosed with Hodgkin's Lymphoma at age 16 and underwent radiation (to the neck, chest and upper abdomen) and chemotherapy ( adriamycin, bleomycin, vinblastine, procarbazine.) She remains in remission with good health. She reported dysphagia and constipation for which she underwent endoscopy for the first time at age 43. Endoscopy showed esophagitis and incidentally she was noted to have numerous colonic polyps of size 5 mm to 10 mm. 25 of those polyps were removed with snare and biopsy forceps. Pathology showed tubular adenoma, sessile serrated adenoma and hyperplastic polyps. She has had a total of 4 colonoscopies with removal of approximately 145 polyps of size 2-5 mm and 13 larger polyps of size 10-13 mm.

No polyps were noted in the stomach or duodenum. She is considering a subtotal colectomy in the near future. Germline genetic testing with a 51-gene panel was negative. She has no Ashkenazi Jewish ancestry and no family history of colon polyposis. The only relevant family history was colon cancer in her grandmother in her 70 s.

We write this case report to increase awareness of this acquired polyposis syndrome. TAP should be considered in patients who develop significant polyposis without known causative germline alteration but who have had prior treatment for a CYAC. The Children's Oncology Group guidelines recommend colonoscopy for CYAC survivors who received abdominopelvic radiotherapy either at age 30 or 5 years after radiotherapy, whichever occurs later, and continue every 5 years.

Introduction ACG guidelines recommend assessment of family history for all patients and referral for genetic testing when indicated. However, the fast-paced nature of clinic visits and high turnover rate of endoscopy units pose significant barriers to this assessment. (Figure) .

Conclusions Male Veterans with high-risk symptoms and prior nongastrointestinal cancer should be prioritized for colonoscopy. The rate of ACN in average-risk equivalent Veterans 45-49 was comparable to average-risk Veterans 50-54, supporting expanding screening to younger populations. High rates of right-sided ACN suggest colonoscopy as a favored screening modality; however, further study is required to determine optimal screening modality in this patient population.

Adenomas risk in Lynch syndrome compared to populations with average and familial risk of colorectal cancer Epidemiology, Biostatistics, and Prevention Institute, University of Zurich, Zurich, SwitzerlandBackground: Adenomas are considered the main precursor lesion for colorectal cancer(CRC) in Lynch syndrome. We aim at describing the adenomas characteristics by gene and compare them to average and familial risk population at index colonoscopy Methods Multicentre retrospective study with inclusion of LS colonoscopy surveillance. We selected the first colonoscopy from nonindex cases and compared adenomas characteristics, prevalence and age of detection between genes, adjusted by age and gender. We then compared them with a retrospective familial risk cohort (FR)(n = 1,099)[1 FDR \ 60-years and/or C 2 FDR with CRC] and an average risk population (n = 3,043). Advanced adenomas (AA) were defined as: C 10 mm in size, high-grade dysplasia, and/or villous component. In the FR and AR cohorts, the ages at first colonoscopy were significantly older than in LS (FR:59(55-64) and AR:51(44-59) vs SL; p = 0.000). Between FR and LS cohorts, no differences were found in the prevalence of adenomas and AA (27.5% vs 16.9%, p = 0.897 and 6% vs 8.4%, p = 0.199). MLH1/MSH2 carriers presented adenomas and AA earlier(p \ 0.002) but no differences on the age of onset were found between MSH6/PMS2 carriers and FR individuals(p = ns). Between AR and LS, we found no differences in the prevalence of adenomas (16.9% vs 32.5%, p = 0.471), although AR individuals were significantly older [50(39.75-59.25) vs 60(55-65), p = 0.000]. The prevalence of AA was higher in AR individuals compared to MLH1/MSH2(AR 10%, p = 0.016), but the age of detection in the AR cohort was older (60 years (56-65); p = 0.000). However, no differences on AA prevalence nor age of diagnosis were detected when comparted to MSH6/PMS2 carriers(p = ns). Conclusions Although the prevalence of adenomas and AA in LS is similar across genes, the age of onset is older in MSH6 and PMS2 carriers, resembling AR and FR populations. These results support personalized CRC surveillance strategies based on the affected gene.

Comparison of novel healthcare delivery models on the uptake of genetic education and testing in families with a history of pancreatic cancer: The GENetic Education, Risk Assessment, and TEsting (GENERATE) Study (KFM)); or were first-degree relatives of PDAC patients (no KFM). Participants were recruited through six academic centers, patient advocacy organizations, and online outreach. Enrollment occurred through the study website (www.GENERATEstudy.org). Study participation was remote, including at-home genetic testing. Participants were cluster randomized at the family level. Arm 1 included remote genetic education via a live interactive session with a genetic counselor on a video-based telemedicine platform (Doxy.me) plus testing through Color Genomics. Arm 2 included remote genetic education via a pre-recorded video plus testing through Color Genomics. Results Between 5/8/2019-6/01/2021, 423 families were randomized, comprising 595 participants. Recruitment occurred via healthcare providers (n = 128, 21.5%), family members (n = 271, 45.5%), and friends, advocacy groups, and online outreach (n = 223, 37.5%). Participants were referred from six GENERATE academic centers (n = 270, 45.4%) and other institutions (n = 325, 54.6%). Study participants were 52.5 years on average, primarily identified as White (n = 577, 97%), and from the Northeast (n = 184, 30.9%). 296 participants were randomized into Arm 1 and 299 into Arm 2. To date, 527 (88.6%) participants have ordered genetic testing; 253/296 (85.5%) in Arm 1 and 274/299 (91.6%) in Arm 2 (p = 0.049, generalized mixed-effects model) ( Table 1) . 82 PDAC associated pathogenic variants were identified ( Table 2) . Conclusions Remote methods of genetic education and testing are successful alternatives to traditional cascade testing, with genetic testing rates nearly 90%. Participant follow-up will assess if satisfaction with decision making, cancer-risk distress, knowledge gained, family communication, and uptake of surveillance were impacted by the mode of pre-test genetic education delivery. In total, 72% of participants had a personal history of (at least one) cancer and 72% had a family cancer history in a close relative. Table 1 shows associations of LS patient characteristics with disease and susceptibility perceptions; Table 2 shows rates and Background Patients with Lynch syndrome (LS), an autosomal dominant inherited cancer syndrome caused by pathogenic germline variants in DNA mismatch repair genes, have an increased risk of colorectal cancer (CRC). Diets high in alcohol, red and processed meats and low in calcium, dairy, and fiber intake (including leafy vegetables and whole grains) have been associated with increased risk for sporadic CRC. We sought to investigate whether dietary risk factors may also affect risk for colorectal neoplasia (CRN) in patients with LS.

Methods Fourteen patients with genetically confirmed LS were enrolled in the University of Michigan Family Microbiome Initiative from 2014 to 2021 through Hereditary cancer clinic. At baseline, demographics and dietary information and were collected using a general questionnaire and a food frequency questionnaire that captured their general food intake over the past year. Subjects submitted stool samples for microbiome analysis. We investigated the differences in several food groups and Healthy Eating Index (HEI), a score used to approximate food-based diet quality. In order to compare subjects with and without a history of colorectal neoplasia, we used Wilcoxon's ranks sum test for continuous variables and Fisher's for categorical variables.

Results Of the 14 subjects the median age at enrollment was 52 years (IQR: 38-64) and 75% were female. Four (27%) individuals were diagnosed with adenomas with a median age of diagnosis at age 60. There were no differences in age, body mass index (BMI), energy intake, alcohol, red meat, processed meat, Patients under 50 years old feel colonoscopies are a greater inconvenience and are more concerned about its side effects than patients 50 years and above (p=0.0118, p=0.0115) Patients with a family history of LS in a close relative are more concerned about colonoscopy side effects than those without family history (p<0.001) but are more likely to recommend colonoscopy to another person with LS (p=0.0122) Findings: Both men and women feel more reassured of cancer protection from a colonoscopy than they do aspirin (p<0.001) Both men and women found aspirin to be more convenient than a vaccine (p=0.0024, p<0.001) and believe that aspirin would have lower side effects than a vaccine (p<0.001) EMERGING PREVENTION OPTIONS 1-Oral medication 2-IV immunotherapy 3-Vitamin rich beverage 4-Gene therapy 5-LS specific vaccine 6-Diet/Nutrition feedback 7-Calorie restriction/Fasting 8-Intensive exercise 9-Yoga 10-Acupuncture Patients with a +FHx are more likely to participate in IV Immunotherapy studies than patients with -FHx (p=0.0264) Patients with +FHx perceive IV Immunotherapy as having a higher prevention benefit than patients with -FHx (p=0.0150) Men believe IV Immunotherapy is more inconvenient than a vaccine (p=0.0014) Fig. 2 LS patient perceptions of current and emerging cancer prevention options (scored 1 = low to 9 = high) Abstracts dairy, vegetables, dietary fiber consumption and HEI score according to CRN diagnosis. Conclusion Although we did not find an association between dietary factors and risk for colorectal neoplasia in patients with LS, we recognize this analysis was limited by the small sample size. We plan to increase enrollment of LS and future studies will correlate microbiome composition with diet to identify potential markers to predict risk for CRN in LS (Table 1) . Background GISTs are most often sporadic, resulting from somatic (non-inherited) mutations in the KIT or PGDFRA genes. GISTs which test negative for these by IHC or molecular analysis are considered ''wild-type GISTs'' resulting in a referral for a genetic evaluation. Additional clinical features for genetics referrals include 3 or more primary GISTs in an individual or 3 or more close relatives with GISTs. Tumor genomic analysis has become an important tool for identifying mutations in individuals who may have an inherited predisposition to GISTs. Germline mutations in KIT, PDGFRA, NF1 and the SDH genes increase the risk for GISTs and have implications for screening for additional cancers as well as cascade testing for family members. (1), MUTYH monoallelic (1). The mean age of diagnosis was 35. The majority were c-KIT positive. Four tumors were located in the stomach, 2 were small bowel and one was para-esophageal. Four had additional malignancies. Only the proband with a KIT germline mutation had a family history of a GIST, also early onset, and the proband had multiple GISTs. Conclusions Our data suggest early age of diagnosis as the strongest predictor for a germline mutation. Family history and c-KIT status were unreliable predictors. Tumor genomic analysis is currently the most efficient way to identify individuals who may carry germline mutations related to GISTs (Table 1) .

Germline pathogenic variant/likely pathogenic variant incidence in individuals with colorectal cancer stratified by age at diagnosis Results We identified 13 (0.8%) CRC patients with confirmed (9) or suspected (4) germline PV in the ATM gene, compared to 0.5% in the general population using gnoMAD v2.1.1 (RR 1.5, 95% CI 0.9-2.7, p = 0.13). ATM PV clustered in the FAT and kinase domains. We had paired tumor sequencing for 6 confirmed germline cases and all 6 (100%) showed a second somatic ATM PV; 3 sequence changes and 3 with loss of heterozygosity (LOH) of the ATM locus (Table 1) . Among the 154 CRC cases without a germline ATM PV but with tumor sequencing results, 66 (30%) had a somatic ATM PV or LOH of the ATM locus. The difference was statistically significant (Table 2 ; p = 0.0009). Conclusion While we did not find substantially increased prevalence of germline ATM PV in our CRC cohort, our data support that a subset Germline classification is conflicting depending on laboratory (ranging to variant of uncertain significance to Pathogenic) *VAF was identical in germline and tumor samples at 24%. Reference allele bias accounts for the lower than expected VAF **Patient 3 also carried a germline pathogenic NBN Slavic Founder mutation, p.K219Nfs*16, c.657_661del ***Patient 6 also carried a germline pathogenic CHEK2 p.T367Mfs*15, c.1100delC mutation VAF = variant allele fraction NM_000051.3 is the ATM reference transcript used for mutation annotations Abstracts of CRCs are caused by germline ATM mutations with acquired second-hits in the ATM gene. More studies are warranted to determine if ATM PV are associated with increased risk of CRC. We hypothesize that a subset of specific ATM PV in certain domains may be associated with higher CRC risk. Background Cascade testing for cancer predisposition is the process of identifying and testing at-risk relatives after identification of a pathogenic variant in a proband. This allows for cancer prevention in unaffected relatives. Standard practice for genetic counselors includes ascertaining a three-generation pedigree and educating the proband to inform relatives of their risk and options for testing. However, this approach typically leads to only 3-4 relatives being tested. We sought to increase uptake of cascade testing by identifying distant relatives via public genealogical database, which also facilitated germline variant reclassification for one family. ). Both received genetic counseling and three-generation pedigrees were obtained (and showed no relationship connection). However, both probands were from the same small town in Ohio. The genetic counselor used public genealogical database, Ancestry.com, with available birth/death certificates, marriage certificates, and census records to link the probands.

Results The probands linked to common ancestors from the 1800s, confirming they were 3rd cousins ( Fig. 1 ). Co-segregation analysis using Thompson et al. 2013 full-likelihood method (PMID 12,900,794) showed a 2328:1 likelihood supporting pathogenicity. This led to reclassification of the VUS as pathogenic. Once linked, 6 additional branches of 3rd cousins were identified, and ultimately thousands of additional distant at-risk relatives. To date, 148 relatives of the two probands have undergone cascade testing (52 positives) and another branch segregating the variant was identified. Ninety-two tested individuals were greater than 3rd-degree relatives to at least one of the probands, and many were not on the original pedigree(s).

Conclusion Utilizing public genealogical databases for families with the same rare variant can significantly increase cascade testing and assist in variant reclassification by identifying the furthest common ancestor. Opportunities for future research should consider how to alert distant relatives of their risk. We recruited individuals with LS through clinics at a large urban teaching hospital in central Canada and at-risk relatives through snowball sampling. We distributed an online survey to evaluate the informational resource with Likert scale questions assessing the informational content, perceived clarity, comprehension, convenience, feelings provoked, and reactions triggered. We compared the responses between those who shared the resource with relatives and those who did not and used multivariable logistic regression to identify predictors of use. We also performed in-depth individual interviews as part of this mixed methods study (presented separately).

The new informational resource was graded at an eighthgrade reading level according to four common readability scales. A total of 92 participants provided feedback on the informational resource through the online survey (response rate 71%). Respondents strongly agreed the informational resource was easy to understand and 67% used or intended to use the resource to inform their relatives. The informational content, perceived clarity, comprehension, and convenience were highly rated. Among those who did not share the informational resource, 88% indicated their relatives were previously informed. Logistic regression analysis revealed that individuals age 45 or older were about four times more likely to share information about LS with their relatives. A need for increased access to reputable online resources was identified. Background In the past decade, many centers have implemented universal screening for Lynch Syndrome (LS) and established multidisciplinary clinics for annual follow-up, generating tremendous potential for cancer prevention. Alerting at-risk individuals to genetic testing and cancer prevention strategies remains reliant on communication within families. There is limited data on barriers and facilitators to cascade testing in Canada, where the universal health care system reduces financial barriers. Using a mixed methods approach, we sought to address a gap in the literature by identifying perceived barriers and facilitators to cascade testing within this patient population. We also developed and assessed an informational resource to facilitate family communication.

Methods We recruited individuals with LS through clinics at a large urban teaching hospital in central Canada. We conducted a survey with 92 respondents (reported separately) and semi-structured interviews with 15 participants to assess the barriers and facilitators to accessing genetic counselling and testing for LS and evaluate the informational resource. Telephone and web-based interviews were audio recorded, transcribed verbatim, and coded inductively by the first author using thematic analysis. The analysis was validated by two additional team members. Results All participants indicated genetic testing was accessible and the barriers identified related to information sharing. There were three major themes impacting family communication about LS: perceptions of genetic testing, family dynamics, and level of acceptance towards relatives' autonomy. Individuals who were the first person in their family to have LS identified more challenges informing relatives. A need for increased awareness of LS among primary care providers was identified, as was access to online resources. Participants who were frustrated by their relatives' decision to decline genetic testing would support direct contact between their healthcare provider and their relative to facilitate communication. The newly developed informational resource was positively appraised by participants, particularly in terms of reading level, comprehension, and sensitivity. 2 We examined the contribution of CFTR variants to pancreas cancer risk in our pancreas GTS patients, a diverse population, to explore whether pancreatic cancer risk in CFTR carriers varies across different racial and ethnic groups. Methods We reviewed self-reported race and ethnicity data and genetic test results for patients seen at pancreas and breast GTS, which served as our control population, from June 2018 to September 2021. There were 60/411 and 49/480 eligible heterozygous CFTR mutation carriers in the pancreas and breast GTS cohorts, respectively. Individuals with chronic pancreatitis, other pathogenic mutations known to be associated with pancreatic cancer risk, or with more than one CFTR mutation were excluded due to the possibility of subclinical cystic fibrosis. Results The odds of having a single CFTR pathogenic variant was greater in the pancreas cohort over the breast cohort (OR 1.4), and was statistically significant (p = 0.0233) [ Fig. 1 ], consistent with a previous study 1 and confirming that our breast GTS population served as a reasonable control population. The non-white cohort had higher odds of having a CFTR pathogenic variant than the non-white breast cohort (OR 1.9; p = 0.02743), with black cohort having the highest odds ratio of any racial or ethnic group (OR 2.6). [ Table 1 ]. Conclusions Our data suggest that CFTR mutations serve as a moderate risk factor for pancreas cancer, especially in non-white populations. Given our limited sample size, more attention is warranted in explaining this trend, especially looking at the poly 5 T tract in the black population, who have the highest rate of pancreatic cancer in the United States. 3 Fig. 1 This graph illustrates the percentage of total CFTR heterozygotes observed in our pancreas (13.6%) and breast (9.5%) populations. The pancreas cohort had significantly more CFTR heterozygotes than the breast cohort (p. = 0.03005). We also compared the percentages of total CFTR heterozygotes as well as percentages of poly 5 T tract variants (11/TG, 12/TG) between the pancreas and breast cohorts across various ethnicities [Asian, Black, Hispanic, and White (Non-Hispanic)]. There was no significant difference observed between the white breast and pancreas cohorts for total CFTR heterozygotes (p = 0.19215) or poly 5 T tract variants (p = 0.39743). However, there was a significant difference observed between the non-white breast and pancreas cohorts for both total CFTR heterozygotes (p = 0.01923) and poly 5 T tract variants (p = 0.0197). Given the small sample size, we were unable to calculate significance within the non-white ethnicities. The general population column represents population data from gnomAD Background Constitutional mismatch repair deficiency (CMMRD) is caused by biallelic mismatch repair pathogenic variants and is characterized by childhood hematologic malignancies, brain tumors, Lynch syndrome related cancers, and dermatologic lesions seen in neurofibromatosis. It is critical to appropriately establish a diagnosis of CMMRD to guide risk counseling, medical management, and clarify risk to other family members. The CMMRD International Consensus Working Group has recently established diagnostic criteria1. Case presentation A 24 year old male from non-consanguineous parents presented with five synchronous colon cancers in the setting of numerous adenomatous polyps. His maternal uncle had rectal cancer at age 50. Genetic testing, revealed a likely pathogenic variant (LPV) c.3227 G [ A, and a variant of uncertain significance (VUS) c.2276 T [ C, in MSH6. The LPV was paternally inherited and the VUS maternally. The patient subsequently was diagnosed with a low grade glioma, a rectal tubulovillous adenoma with high grade dysplasia, and a pouch cancer. There were no neurofibromatosis dermatologic manifestations. The presenting colon and pouch cancers were microsatellite stable but there was patchy expression of MSH6 in the tumor and normal tissue. Per CMMRD diagnostic criteria, the patient has a likely diagnosis of CMMRD. Discussion There are limited data available about future cancer risks with atypical CMMRD; more research is needed. Additional and close follow up for patients with CMMRD is needed. In the interim, this patient was advised to undergo full screening for CMMRD associated cancers. Genetic testing recommended for his maternal uncle and brother (Fig. 1, Table 1 ). Table 1 The pancreas GTS cohort included 411 individuals, 60 of which had a single CFTR mutation. The breast GTS cohort had a total of 480 individuals, 49 of which were CFTR heterozygotes. Excluding poly 5 T variants, the odds of individuals from the pancreas cohort having a CFTR mutation was greater than the breast cohort (OR = 1.4), which is consistent with a previous study [McWilliams et al., 2010] . Of note, the odds of black individuals in the pancreas cohort having a single CFTR mutation was much higher than the breast cohort (OR 2.6). General population data represents population data from gnomAD Abstracts Fig. 1 The percentage of total CFTR heterozygotes observed in the pancreas cohort was greater than the breast cohort, 14.6% and 10.2% respectively [a]. The pancreas cohort had significantly more CFTR heterozygotes than the breast cohort (p. = 0.0233). We also compared the percentages of total CFTR heterozygotes as well as percentages of poly 5 T tract variants (11/TG, 12/TG) between the pancreas and breast cohorts across various ethnicities [b] . There was no significant difference observed between the white breast and pancreas cohorts for total CFTR heterozygotes (p = 0.14917) or poly 5 T tract variants (p = 0.31918). However, there was a significant difference observed between the non-white breast and pancreas cohorts for both total CFTR heterozygotes (p = 0.02743) and poly 5 T tract variants (p = 0.04093). Given the small sample size, we were unable to calculate significance within the non-white ethnicities, besides Asian which was not statistically significant. The prevalence of poly 5 T tract variants in the non-white races appeared greater in the pancreas cohort than the breast cohort, marked by the arrows [b], although significance could not be measured due to small sample size. General population data represents population data from gnomAD Background Individuals with truncating alterations in the APC gene typically present with a classic or attenuated form of familial adenomatous polyposis (FAP/AFAP). The mechanism for pathogenicity of nonsense and frameshift alterations in loss-of-function genes is well established to be premature protein truncation and/or nonsensemedicated decay (NMD); however, N-terminal truncations may be an exception due to incorrect annotation or several rescue mechanisms including use of multiple translational start codons, translation reinitiation, use of unconventional (non-AUG) translational start sites, and/or escape of NMD. As such, review of genotype-phenotype correlations for N-terminal truncations in highly penetrant genes may reveal atypical clinical presentations. Here, we identify a group of APC truncations in which the premature termination codon is within Abstracts the first several amino acids of coding exon 1 in patients without a polyposis phenotype. Case presentation The clinical data for three patients, tested at a commercial diagnostic laboratory, with unique truncating alterations in APC and whose personal and/or family histories do not exhibit the classic or attenuated colon polyposis/cancer diagnoses are presented (Table 1) . Information was ascertained through the test requisition form. Limited family member testing is available for only one case. Discussion Although the identified alterations are located near or within a highly conserved amino-terminal oligomerization domain that has been established as a critical region for proper dimerization to occur (Fig. 1) , there is a lack of published data on truncating alterations impacting only the 5' region of this domain. Further, there is a lack of truncating alterations detected in patients with a FAP/AFAP phenotype in multiple databases (including HGMD, ClinVar, and LOVD) upstream of p.R24*, a well described pathogenic alteration. We postulate that one mechanism for this phenomenon may be related to the presence of an in-frame methionine at amino acid position 18, that may serve as an alternate translational start. The variants associated with the phenotypes described here fall short of the attenuated phenotype typically described in distal APC truncations. This case series highlights the importance of careful consideration for N-terminal truncating variants and the historic assumption that they unequivocally produce loss-of-function transcripts or polyposis phenotype. [1] . To prevent and detect cancer and decrease mortality, early identification of those with LS is critical [2] . Immunohistochemistry (IHC) testing is now considered the gold standard screening modality for Lynch Syndrome regardless of clinical and family history [3] . Despite this recommendation, referrals for germline testing in the case of abnormal IHC results is often complicated and can lead to missed opportunities. Thus, our institution implemented the Hereditary Cancer Screening and Risk Reduction Program (HCSRRP) to facilitate counseling and genetic testing for patients identified as high-risk for familial cancer syndromes. The purpose of this study is to describe and assess the impact of the HCSRRP on uptake of genetic counseling and testing by pathologyidentified patients at high-risk for LS. Methods Adult patients identified as high-risk for LS as defined by abnormal IHC stains for MLH1, PMS2, MSH2, and MSH6 in any tissue specimen were included. The pre-intervention cohort constituted patients identified by pathology between January 2013-August 2014 and post-intervention between January 2017 and March 2020. Data were abstracted from electronic medical records, the Department of Pathology's clinical database, and the HCSRRP visit logs. Statistical analysis was performed using SAS.

Results 42 patients were identified in the pre-intervention cohort and 151 patients were identified for the post-intervention cohort. Before implementation of the program, 6.3% (N = 2) of pathology-identified high-risk patients were seen by a genetic specialist (Fig. 1) . After implementation, 35% of patients had at least one visit with the HCSRRP for genetic counseling, and 54% of patients underwent genetic testing. Age and cancer type were significantly associated with uptake of genetic testing, with patients younger than 65 years old and those with gastrointestinal or gynecologic cancer having higher testing rates (p = 0.01543, p = 0.0082 respectively).

Conclusions Implementation of a designated hereditary cancer program had a significant impact on the proportion of patients identified as high-risk for Lynch Syndrome who visited with a genetics specialist and underwent genetic testing. Conclusions Our risk estimates were comparable to prior studies, including those that utilized clinic-based ascertainment with complex analyses correcting for ascertainment bias. This finding suggests that these analyses accurately correct for clinic-based ascertainment, reducing the likelihood of inflated penetrance estimates. Our data support the continued use of gene-specific guidelines and current colorectal cancer screening recommendations. However, it is possible that gynecologic management guidelines may need to start at an earlier age, given the large proportion of early-onset endometrial and ovarian cancers. Unusual location of a juvenile polyp in juvenile polyposis syndrome -a case report Background Juvenile Polyposis Syndrome (JPS) is a rare hereditary hamartomatous polyposis syndrome due to a pathogenic variant (PV) in SMAD4 or BMPR1A. It is associated with a risk of colorectal and gastric polyposis and cancer, and rarely small bowel polyps. Guidelines suggest endoscopic surveillance in JPS begin at the age of 15 years old with upper endoscopy and colonoscopy and repeated no less frequently than every 3 years pending findings. No recommendations are made for small intestine surveillance as the evidence of small bowel involvement in not well established. Case presentation We report a 29 year old female patient with a personal and paternal family history of JPS and hereditary hemorrhagic telangiectasia. The patient was diagnosed with a pathogenic variant in SMAD4 at the age of 10 years after presenting with rectal bleeding. She underwent a restorative proctocolectomy with ileal pouch-anal anastomosis at age 15 for colorectal polyposis. She since then has been having upper endoscopy and pouchoscopy every 2-3 years. In July 2021 pouchoscopy was normal. Upper endoscopy demonstrated numerous sessile polyps up to 10 mm in size at the cardia removed with a hot snare. The rest of the stomach was normal. The duodenum was normal except for an abnormal appearance of the papilla which was biopsied. Pathology of the polyps at the cardia and of the papilla was juvenile polyp negative for dysplasia. Discussion We describe the first reported case of a patient with JPS due to a PV in SMAD4 with involvement of the major duodenal papilla with juvenile polyp histology. The patient has no symptoms attributed to the duodenal papilla involvement and will undergo repeat EGD in one year. We believe this a rare finding and warrants further research. Conclusions These findings support the success of screening and prevention efforts at reducing colorectal and endometrial cancers, thus lengthening the lifespans of LS patients. As a result, the incidence of extracolonic LS cancers among older individuals is increasing. Our data also suggest that immune status may play a role in the development of LS cancers (Fig. 1) . Fig. 2A) . Similarly, KEGG pathways included positively enriched Chemokine Signaling and Jak Stat Signaling (Fig. 2B) .

Conclusion Differentially expressed genes and enriched pathways that overlap in SPS-SSL (but not AP) and EoE suggest allergic and/or immune-based etiologies as drivers of SPS development. Further studies of genes, pathways and clinical correlations in these and other cohorts may assist prevention and treatment of SPS and EoE. Case presentation A 64 year old female with FAP presented for ongoing EGD polyposis surveillance. Previous EGD revealed more than 100, 2-9 mm gastric polyps in the cardia, fundus and gastric body and Spigelman stage I duodenal polyposis. Additionally, an 80 mm flat WMP (Fig. 1) was noted in the proximal gastric body along the greater curvature of the stomach. Multiple biopsies of the white patch revealed gastric adenoma with low-grade dysplasia. Due to the high risk nature of this lesion, we decided to pursue en-bloc resection using ESD for complete resection of the neoplasm. The WMP was approached in retroflexion and a ProdiGI traction wire (ERD-TW35, Medtronic, Dublin, Ireland) was used for traction. Complete en-bloc R0 ESD resection was achieved. Post resection histology showed the foveolar-type gastric adenoma with low grade Abstracts dysplasia. The patient went home after the procedure and was doing well on follow up and had no adverse events. Given the gastric polyposis and high risk histology, surveillance will be continued no less frequently than yearly. Discussion This report describes a novel application of ESD in patients with FAP and WMP. Certain endoscopic features including a carpeting of proximal polyps, polypoid mounds, polyps [ 1 cm, and WMPs are associated with gastric cancer in FAP. High risk histology such as pyloric gland adenoma, tubular adenoma, fundic gland polyp with high grade dysplasia is more commonly seen within and outside of the WMP. ESD allows for complete resection and more accurate histopathological assessment of margins and presence of high-risk histology. 1-3) . Small bowel neoplasia was identified in 3 procedures (1.7%), with 2 adenomatous polyps removed from the distal duodenum/proximal jejunum and 1 duodenal cancer located in the duodenal bulb (Table 2) . No procedural complications were noted. The 3 patients with small bowel neoplasia were women age 45-59 with MSH2 or MLH1 variants. Two had a history of endometrial cancer and none had a history of colon cancer. They did not have a family history of small bowel cancer. The distal duodenal and proximal jejunal adenomatous polyps were found on initial screening enteroscopy in patients that had received previous standard upper endoscopy within 3 years.

Conclusions Push enteroscopy identified distal duodenal and proximal jejunal neoplastic lesions at a rate at least similar to gastric and proximal duodenal neoplasia and these lesions would not have been identified with standard upper endoscopic screening. Given this increased yield, we favor the use of push enteroscopy if upper endoscopic screening is performed in LS (Figs. 1, 2) . None reported family history of brain cancers in a three-generation pedigree. LS-associated PVs were found in 3/100 (3.0%) of participants with brain tumors (all types) and 3/27 (11.1%) when including only those with astrocytoma or glioblastoma. Discussion While LS-related pediatric cancer diagnoses are extremely uncommon and brain tumors are a relatively rare manifestation of LS, this work suggests that when cancers develop in children with LS this may be a common site. Brain cancer screening is currently not part of standard medical management for individuals with LS. These findings raise the question of the appropriate age for predictive testing and indicate a possible role for education on signs of neurological cancers and/or screening in younger individuals with LS. Additional work in this area could further inform a possible role for germline genetic testing for LS in pediatric patients with astrocytoma and glioblastoma given that LS-related germline PVs were identified in more than 10% of patients in this population with these cancer types (Table 1) . Results We identified cmAPC mutations in 18/28 cases (64%). Half (9/18) of patients with mosaic APC had the mutation detected only in polyps, with mosaic mutations detected at low allelic fractions in the germline sample of the remaining cases (9/18). In 10/28 cases (36%), independent APC mutations were detected in each of the tested polyps, making a diagnosis of FAP less likely. Compared to patients with apparently sporadic polyposis, patients with cmAPC mutations were younger at diagnosis (Wilcoxon rank sum test, one-tailed, W = 24, p = 0.0008) with median age 49 years (range 13 to 61 years) compared to 62 years (range 30 to 72 years) (Fig. 1) . Patients with cmAPC mutations had more polyps (Wilcoxon rank sum test, onetailed, W = 125, p = 0.048), with a median of 41 polyps (range 10 to 300) compared to 25 (range 10 to 63) in patients with sporadic polyposis (Fig. 2) . Conclusion Testing multiple adenomas with a paired germline sample using the 3-sample ColoSeq Polyposis technique effectively identifies constitutionally mosaic APC mutations in patients with unexplained polyposis, particularly among patients under age 60 with greater than 30 adenomas.

Background Lynch syndrome (LS) accounts for approximately 2-3% of colorectal (CRC) and endometrial (EC) cancers and is the most common inherited cause of these malignancies. Evidence-based recommendations support testing for LS on all newly diagnosed CRCs and ECs. The Lynch Syndrome Screening Network (LSSN) has promoted institutional implementation of universal tumor screening Abstracts for LS (UTS-LS) and collaborative data collection over the past decade.

Methods Since LSSN was launched in 2011, interested institutions have joined by completing annual membership applications that included information regarding their existing UTS-LS protocols, and the number and type of LS cancers screened since 2008. Application and renewal information received between 2011 and 2020 was analyzed to determine trends in membership and tumor screening.

Results In 2011, 91 institutions joined LSSN. This number dropped in 2013 to 80 institutions and to 72 institutions in 2018-2020. In 2020, 85% of member institutions reported routine screening for LS on all or a subset of newly diagnosed CRCs. Of these institutions, 97% screen all cases, an increase from 56% in 2012 and 81% in 2013, while the remainder limit by age or other selection criteria. In 2013, 21% of member institutions reported screening all ECs, which increased to 53% in 2020. For both CRCs and ECs in 2013, immunohistochemistry was the most common initial screen (79% and 87%, respectively), which increased to 92% and 95% in 2020. In 2012, 44% of reporting institutions indicated that their genetics department is responsible for reviewing all screens and initiating follow-up on abnormal screen results for CRCs. This changed slightly to 47% by 2020. There was a clear increase in the number of cancers screened over time with over 42,000 cancers screened from 2008 to 2018 (Fig. 1) . Over half of the institutions with existing or soon-to-be implemented protocols indicated their willingness to provide additional patient-level data.

Conclusions LSSN is an important resource to support, track, and promote UTS-LS through collaborative data collection. This membership data demonstrates an increase in the rates of UTS-LS among LSSN member institutions and suggests there is significant interest in collaborative data collection among institutions involved in cancer genetics.

Risk of malignant and benign thyroid disease in patients with familial adenomatous polyposis -a prospective surveillance study

Introduction Patients with familial adenomatous polyposis (FAP) are at high risk to develop colorectal, ampullary or duodenal cancer. FAP is furthermore associated with a substantial lifetime risk for thyroid cancer (TC) and benign thyroid disease. Screening and surveillance guidelines differ substantially between countries. The aim of our study was to assess the prevalence of TC and benign thyroid disease and possible surveillance intervals in a large European center.

Methods We identified consecutive patients with FAP at a single center from 2010 till September 2020. Inclusion criteria were a known pathogenic variant in the APC gene and age [ 18 years. All patients were enrolled in our prospective hereditary cancer registry and signed an informed consent. Thyroid surveillance consisted of ultrasound and endocrinologic testing for thyroid disease. We collected demographics, ultrasound, laboratory and histopathological results in case of biopsy or surgery.

Results A total number of 230 patients with FAP were part of our prospective registry. We had to exclude 15 patients (\ 18 y), 28 patients refused to undergo thyroid examination.

In 187 patients (100 female; mean age 39 (± 15 y); 187 (100%) pathogenic variant in the APC gene) at least one thyroid examination was performed at our center. Endocrinologic testing for thyroid disease revealed abnormal results in 92/187 (49%) with hypothyreodism diagnosed in 32/92 (35%). In 85/186 patients (46%) thyroid nodules were detected with a significant female predominance (55/99 vs 31/87; p = 0.01). In 16/187 patients (mean age 41 (± 13y) thyroid surgery was performed revealing thyroid cancers in seven patients, adenoma in one patient and C cell hyperplasia in additional one (Table 1) . No patient reported any symptoms prior surgery. Autoimmune thyreoiditis (AIT) was diagnosed in 28/187 (15%) patients with a female predominance (21/99 vs. 7/87; p = 0.012), including one patient with thyroid cancer.

In 101 patients, a surveillance examination was done with an interval between 1-3 years. In patients with a normal index examination, no cancer or large thyroid nodule ([ 5 mm) was observed.

Conclusions Patients with FAP are at increased risk for developing benign and malignant diseases of the thyroid gland irrespective to gender. Our data indicate that if the index examination is inconspicuous, the examination interval may be extended. Results At least one esophagogastroduodenoscopy with mucosal biopsy was performed in 129 proven carriers of a pathogenic variant since 2008. Two new cases of gastric cancer, three new cases of duodenal cancer and one ampullary cancer were observed (age 50-71 years) during routine endoscopic surveillance. The detection of (pre-) neoplastic upper gastrointestinal lesions was often associated with the occurrence of synchronous LS-associated cancer (7/11 patients, 64%; Table 1 ). One MMRd crypt focus adjacent to a duodenal carcinoma was detected (Image 1). Cancer was detected in patients with and without prior endoscopy (time since last endoscopy 0-48 months).

Conclusion This prospective endoscopic study shows that surveillance of the upper GI tract identifies clinically relevant results in a large proportion of LS patients. The primary endpoint is to compare the 10-year cumulative incidence of upper GI tract neoplasms (gastric cancer and duodenal cancer) between surveillance strategy and symptom-triggered endoscopic examinations in an international setting. Further, we want to identify factors associated with a higher risk to develop upper GI cancer. We intend to provide the basis for systematically assessing the relation of immune surveillance with upper GI cancer risk. To address these important questions, we plan to conduct the study as a joint project of the European Hereditary Tumor Group (EHTG) and The Collaborative Group of The Americas on Inherited Gastrointestinal Cancer (CGA-IGC).

Ampullary adenomas in patients with familial adenomatous polyposis (FAP): Biopsy, management, risk assessment Introduction After colectomy has been performed in patients with familial adenomatous polyposis (FAP), ampullary and duodenal cancer are the leading causes of death. Risk stratification of duodenal polyposis and cancer risk is based on Spigelman stage. It is not defined, whether the papilla is part of the Spigelman staging system.

We identified consecutive patients with FAP at a single center from January 2012 till September 2020 with at least one upper GI endoscopy. Patients with a forgegut surgery (Whipple procedure or pancreas-sparing duodenectomy) were excluded. We collected demographic, endoscopic and histology data and calculated Spigelman stage with and without papilla results. Results A total number of 213 patients with FAP were part of our prospective registry. We had to exclude 19 patients due to prior upper GI surgery. In 193 patients (189/193 (98%) a pathogenic variant in the APC gene; 103 female; mean age 36.6 (± 16 y)) out of 213 at least one upper GI endoscopy with ampullary biopsy was performed at our department. In 89/193 patients (46%) an ampullary adenoma was detected, in 75/89 cases mascroscopically suspected and confirmed by histopathology, in 14/89 cases only detected via routine biopsy. The inclusion of the histopathological result into the Spigelman score led to an upgrade in 16 cases (7%), with consideration of prophylactic duodenectomy for 2 patients (1%). No adverse events effects were observed following ampullary biopsy. The size of the ampullary adenoma led to an upgrade in 25 patients (28%) and consideration of prophylactic duodenectomy in 4/89 patients (4%).

Four-teen patients underwent a papillectomy at our department. After papillectomy, 6 cases of pancreatitis (42%) and four bleedings (28%; endoscopically managed) occurred. Follow-up data were available for all patients. During follow-up, 6 out of 14 (43%) resection sites demonstrated recurrence. In all six patients, additional EMR and radiofrequency ablation were performed. In 4/6 (67%) patients, a pancreatitis was observed. Conclusions Biopsy of the ampulla is safe and feasible in FAP patients. Histology and size of the papilla can change Spigelman stage and therefore affect patient management. Endoscopic papillectomies showed substantial adverse events, especially interventional treatment for recurrence. Benefits and risks should carefully be weighted (Figs. 1, 2) . Age of onset of surveillance colonoscopy for MSH6 mutation carriers Background Current guidelines by NCCN, the BSG and ESGE stratifying the age of onset of surveillance colonoscopy according to the gene associated with Lynch syndrome (LS). They suggest starting colonoscopic surveillance from age 25 years for carriers of a pathogenic variant in MLH1 and MSH2 and 35 years for carriers with a pathogenic variant in MSH6 and PMS2. Previous studies demonstrated pathogenic MSH6 variants to be associated with the occurrence of CRC at later age compared to MLH1/MSH2 variant with a low risk of CRC before the age of 30 years. However, data on cancer development in MSH6 carriers are sparse. Methods: We analyzed data of our prospective register of the ''German Consortium for Familial Intestinal Cancer'', which currently comprises 2108 patients with LS, including 255 carriers (127 males; 50%) of a pathogenic variant in MSH6.

Results CRCs were observed in 128/255 (50%) MSH6 carriers with a mean age at diagnosis of 47.5 years (range 19-78 years) (Fig. 1) . CRCs occurred more often in the left (75 cases; 59%) than in the right hemicolon (53 cases; 41%), with males being more frequently affected than females (55% vs 45%). Of note, in 19/128 (15%) patients, CRCs were detected before the age of 35 years. Most of the MSH6 carriers with CRC (113/128; 88%) were index patients. A total of 139 MSH6 carriers underwent 749 (range 1-28; mean 5.4) surveillance colonoscopies with a cumulative prospective observation time of 785 person-years. Adenoma detection rate (ADR) by either index or follow-up colonoscopy was 14% overall. Below the age of 35, ADR in index colonoscopies was already 13% and thus just as high as in the age group of 60-69 years (Fig. 2) . This might imply that adenoma formation in MSH6 carriers is already beginning at a young age. Recently published data from Germany, the Netherlands, and Finland showed that adenoma or advanced adenoma incidence was similar or even higher in MSH6 carriers compared to MLH1 carriers.

Conclusion Taken together, we show that CRCs and adenomas were already apparent in a substantial proportion of MSH6 carriers before the age of 35 years. The high number of index cases might lead to an ascertainment bias. However, our data clearly indicate early cancer development in a relevant subgroup of MSH6 carriers. Thus, we believe that colonoscopic surveillance should start before the age of 35 years in these patients.

Clinical characteristics of colorectal cancer cases (CRC) in MSH6 carriers. Age distribution, gender and localizatio of CRC is shown.

Adenoma detection rate (ADR) in MSH6 carriers. Adenoma detection in index and follow-up colonoscopies in different age segments are shown. Prior studies analyzed genetic testing requisition forms (TRF) to identify patients who meet NCCN criteria for genetic testing for LS and/or HBOC 3, 4 . By analyzing self-reported history rather than TRF, data is likely to be more complete, providing a more robust analysis. Methods Participants recruited from two clinical sites at Michigan Medicine (Breast and Ovarian Cancer Risk Evaluation Clinic (BOCREC), University Health Services (UHS)) from 9/1/20 through 6/30/21 were asked to complete an online personal and family health history module at their convenience, on any internet-connected device. The module was written at a 4th grade reading level to reduce literacy concerns. Answers were analyzed against NCCN guidelines 1,2 to determine if participants met testing criteria for LS and/or HBOC. All BOCREC participants were asked to complete the module after referral. UHS patients were invited to complete the module if they had a personal and/or family history of cancer. Not all patients invited to participate did so. Results A total of 723 histories were analyzed, of which 66.11% of patients met at least one testing criterion and 9.82% of patients met both (LS and HBOC) testing criteria. The UHS clinic, which is not designed to identify high-risk patients, had 42.65% of patients meeting at least one criterion, including 11.76% meeting LS criterion and 7.35% meeting both testing criteria. BOCREC, which specializes in seeing patients at increased risk of HBOC, had 10.69% of patients also meeting LS criterion and 10.08% of patients meeting both criteria. Conclusions This study emphasizes the importance of collecting personal health history and multi-generational (3-7 generations) pedigree in all populations, including low-risk populations, to generate appropriate referrals to genetic counseling and/or determine Abstracts appropriate genetic testing. While our study found lower rates of individuals meeting NCCN testing criteria than prior studies looking at TRFs 3,4 , this is not surprising, as the study analyzed all individuals, as opposed to those at the highest risk undergoing testing.

Universal tumor screening for Lynch syndrome through the lens of diversity, equity, and inclusion Background The murder of George Floyd highlighted the ongoing impacts of racism across all aspects of life in America. In response UCSF developed mandatory diversity, equity, and inclusion (DEI) training for providers and staff. We set out to determine if the heightened awareness of DEI issues at UCSF impacted referral patterns after universal tumor screening for Lynch syndrome (LS). Methods Our analysis included all cases of endometrial or colon tumors that were found to have abnormal IHC or MSI through our LS universal tumor screening protocol, separated into two cohorts: Jan 1, 2019 to June 1, 2020 (16 months) and June 2, 2020 to June 30, 2021 (13 months). We captured primary language, race, and ethnicity for all patients with abnormal LS screening, and evaluated whether they were referred appropriately to cancer genetics for follow-up. Cases sent to UCSF for outside pathology review only, diagnosed with LS previously, or had MLH1 promoter methylation analysis ordered after June 30, 2021 were excluded. Results 114 cases were included in our analysis, 49 of which met criteria for referral for genetic counseling to have germline genetic testing; the remaining were determined to have abnormal IHC/MSI due to MLH1 promoter hypermethylation. A higher proportion of individuals who self-identified as African American were not referred (missed referral) compared to those who self-identified as Caucasian (5/8 [62.5%] versus 11/31 [35.5%]). While the overall proportion of missed referrals decreased after June 1, 2020, there was no decrease among individuals who self-identified as African American. There were no differences in referral patterns based on primary language. Conclusion While our overall numbers for these two time periods are small, the heightened awareness of DEI issues and anti-racism initiatives did not seem to impact the disproportionate number of individuals self-identifying as African American who were not referred to genetic counseling following abnormal universal tumor screening for LS. We will continue to analyze this data through the lens of DEI, to more fully understand the barriers leading to this disparity, with the hopes of implementing systemic institutional changes that translate to equitable care for our African American patients. Background Lynch syndrome (LS) is a hereditary cancer syndrome that accounts for the majority of hereditary colorectal and endometrial cancers and approximately 3% of all colorectal cancers. Universal tumor screening has been shown to greatly increase the identification of individuals at risk for Lynch syndrome, and has been implemented at many institutions, but benefit from implementation relies on timely referral and genetic evaluation. To better understand obstacles to diagnosis of Lynch syndrome, our team applied for and was awarded $20 K from the Collaborative Fund of CGA-IGC to create a multicenter cloud-based database for de-identified universal tumor screening records for institutional members of the Lynch Syndrome Screening Network (LSSN). Methods We contracted with a developer to create the database, using database elements developed by the LSSN Database Committee, and housed temporarily on a staging server. In order to add patient records, a graphic user interface to manually input records was created, as well as a bulk upload option by CSV file. A blank CSV template file was created to facilitate other institutions with longstanding databases to map their data for bulk upload. Both methods of adding records were tested for data fidelity by uploading and downloading dummy records from the staging server and any errors were corrected. To ensure that data-sharing requests go through the LSSN, institute accounts cannot view records added by other institute accounts. Once the database was confirmed to work correctly, it was transferred to a live server. This was then tested again to ensure login and account creation, and manual and bulk upload and download, were error-free. Conclusion We have successfully created a cloud-based collaborative database with capability to both manually add and view de-identified records through a graphic user interface, and add or download records in bulk by CSV file. This database was created in collaboration with the LSSN and will be utilized by their participating member institutions to generate a large pool of multi-center universal screening records, allowing for large multi-center studies. Next steps include the finalizing of data use agreements and facilitation of IRB considerations with LSSN member institutions.

Timely and correct diagnosis of constitutional MLH1 methylation at first presentation of cancer Megan P. Hitchins 1 1 Department of Biomedical Sciences, Cedars-Sinai Medical Center, Los Angeles, California 90048, USA Constitutional MLH1 methylation, or ''epimutation'', is a rare cause for a cancer phenotype reminiscent of Lynch syndrome, most frequently colorectal cancer (CRC) and endometrial cancer (EC). Characterized by methylation of one allele of the MLH1 CpG island promoter with allelic loss of expression throughout normal tissues, this molecular mechanism predisposes to early-onset mismatch repair deficient (MMR-d) cancers displaying immunohistochemical loss of MLH1/PMS2 expression, microsatellite instability, and MLH1 hypermethylation. While some familial cases of constitutional MLH1 methylation have been linked to germline non-coding variants (e.g. the c.-27C [ A; c.85G [ T haplotype and promoter deletions), most cases arise de novo and test negative in cancer gene panel testing.

With the presence of MLH1 methylation in the tumors and absence of germline mutations, patients with constitutional MLH1 methylation may be mistaken for more common sporadic MLH1-methylated cancers in universal testing schemes of CRC and EC for MMR-d and Lynch syndrome, or undergo a molecular diagnostic odyssey before the cause of their cancer is diagnosed. Given carriers of constitutional MLH1 methylation are at high risk for metachronous cancers, it is important to diagnose them at first presentation. The selection algorithm with the highest positive detection rate is presence of MLH1 methylation in the tumor of a patient with first cancer presentation \ 60 years of age. While CLIA testing for MLH1 methylation in whole blood samples does identify carriers of this defect, this has led to one case with a false-positive test result, most likely due to the detection of MLH1 methylation within circulating tumor DNA (ctDNA) in the blood plasma originating from an undiagnosed tumor at the time of the blood draw. It is therefore important to perform CLIA testing on leukocyte nuclei, not whole blood. In confirmed carriers of constitutional MLH1 methylation, it is important to test first degree relatives, and/or undertake extended sequencing around the MLH1 gene in the proband to identify potential linked germline non-coding variants. The Hitchins Laboratory has NCI/NIH R01 funding to undertake an extended molecular ''work-up'' of cases with either confirmed MLH1 methylation, or early-onset MLH1 methylated tumors, which includes allelic methylation testing and extended sequencing around MLH1. I am seeking patient samples for inclusion on a collaborative basis.

(colonoids) from this individual for comparative analysis of proliferation and downstream pathway activation. Methods Through whole exome sequencing, an individual with high polyp burden and negative genetic testing for variants in SMAD4 and BMPR1A was identified to have a potentially pathogenic germline variant in BMPR2. Under an IRB-approved protocol, patient-derived, three-dimensional colonoids were established from adjacent colon and polyp tissue of this individual, as well as an individual with a BMPR1A deletion. Proliferation and metabolic activity of each line were measured by Ki67 staining, EdU labelling, and cell titer glo (CTG) assay alongside age-and sex-matched controls. Relative protein expression of known drivers and downstream effectors in colonoids was examined by Western Blot. Results Distinct phenotypic differences are evident between colonoids from an individual with a BMPR1A deletion and both the colon and polyp BMPR2 variant colonoids, such as increased crypt budding and Ki67 staining. CTG assay data indicate higher metabolic activity in BMPR2 variant colonoids in comparison to normal controls (p = 0.0104.) Through Western blot analysis, both BMPR2 colon and polyp colonoids showed decreased SMAD4 expression and phosphorylation and decreased BMPR1A expression. Conclusions These data demonstrate that clear phenotypic differences exist between colonoid lines established from normal controls, individuals with known JPS predisposition genes, and a novel candidate driver of disease, BMPR2. Proliferation and protein expression data suggest that both known and candidate genotypes are consistent with a hyperproliferative phenotype. In vitro data support BMPR2 as a candidate germline driver of the JPS phenotype, and additional study is ongoing regarding downstream pathway regulation in colonoids with a BMPR2 variant. Background There is currently limited data and no guidelines for the management of transgender individuals with inherited cancer risk. We present a case of a young transgender male with newly diagnosed Lynch syndrome (LS) and the complex care considerations of his future management. Case Presentation EN is an unaffected 18-year-old transgender male (assigned female at birth) referred to Genetics for cascade testing, as his father was known to carry a MSH2 PV. Regarding his transition, he took puberty blockers from age 11 and testosterone since age 16. He completed gender-reaffirming top surgery at age 15 but had not thought deeply about plans for gender-reaffirming bottom surgery. His family history of cancer is significant for 2 paternal aunts had colon cancer (CRC) reportedly diagnosed as early as age 20, synchronous uterine and ovarian cancer in an aunt diagnosed in her 40 s, and sebaceous adenomas in his father. He consented to a 77-gene germline genetic testing panel and was found to carry the familial MSH2 PV only. He was recommended to return to Genetics for a physical exam and to coordinate his first colonoscopy screening. Discussion This case brings several biopsychosocial considerations to light, namely that there is little data and no formalized recommendations for cancer screening of trans individuals with LS. As such, we are following the current NCCN guidelines while thoughtfully attempting to tailor this patient's care plan to account for his genderrelated healthcare. We are discussing the timing and impact of a riskreducing hysterectomy/salpingo-oophorectomy, which intrigued him because this procedure would have been considered elective in the (Fig. 2) .

Conclusions Results from this analysis revealed a clinical gradient correlated with origin of mismatch repair deficiency, in which DS lies between LS and MLH1-hm with respect to age of onset. Paired testing outcomes are correlated with clinical presentation; thus, this data can help inform testing and management decisions for CRC patients. (Table 1) .

No association between MMR PV and BE was observed.

Conclusions In our cohort, BE occurred 2 9 greater than observed in the Kumar study, the only other LS related EGD surveillance program reporting BE (Table 1) . Neither ours nor Kumar's study reported the frequency of gastroesophageal reflux (GERD), the greatest risk factor for BE. The BE prevalence and frequency of BE-related dysplasia in our study is similar to a meta-analysis by Eusebi of adults in North America with GERD symptoms (Table 1) . Although we had only 1 BE-related EAC, this is 3 9 more common than reported in the Eusebi study. This may represent a synergistic risk between BE-related dysplasia and LS mutagenesis although we found no association between BE and a specific MMR PV. Larger studies are needed to determine if the risk of BE and BE-associated neoplasia is higher in patients with LS, including those with and without GERD. (Table 1) .

Conclusions Despite Medical Policy supporting GGT for all pts with CRC, \ 10% of eligible pts received testing. If all CRC pts enrolled in the health plan in 2020 had received GGT, potentially * 6,300 additional pts with PGVs conferring potential eligibility for precision therapy (PD-1/PD-L1 inhibitors), clinical treatment trials (PARP inhibitors) and/or specific management recommendations including counseling and cascade testing in relatives, could have been identified, but were missed. Additional research is needed to identify obstacles to systematic implementation of this Medical Policy and to improve access to underrepresented populations. Background Long-term survival for individuals with pancreatic ductal adenocarcinoma (PDAC) is rare. Anecdotally, we observed that long-term survivors referred to our clinic for genetic testing seemed more likely to have pathogenic variants (PV) identified in PDAC-susceptibility genes. This study aims to determine if our observation was borne out by data or simply due to an ascertainment bias.

Methods We queried our pancreatic cancer database (PAGER) to identify individuals with PDAC who underwent genetic testing (n = 393) and selected individuals diagnosed at least 5 years ago. The PV prevalence rate of individuals with greater than 5-year survival (n = 34) was compared to individuals with less than 5-year survival (n = 155). An independent cohort of individuals (n = 186) who were ascertained in a consecutive manner through participation in a universal genetic testing study was used to represent our baseline prevalence rates in unselected cases. Since that study was completed less than 5 years ago, we defined long-term survival as more than 4 years for this group.

Prevalence was compared with Chi2 tests. Results In our PAGER cohort, 10 of 34 (29.4%) 5-year survivors had a PV in a PDAC-susceptibility gene, whereas 30 of 155 (19.4%) individuals who lived less than 5 years after diagnosis had a PV (p = 0.19). See Table 1 for PAGER cohort characteristics. In our universal testing cohort, 1 of 20 (5.0%) 4-year survivors had a PV in a PDAC-susceptibility gene, whereas 16 of 166 (9.6%) less than 4-year survivors had a PV (p = 0.50). See Table 2 for the universal testing cohort characteristics.

Conclusions Our data suggests that the higher PV prevalence rate seen in our long-term PDAC survivors is the result of ascertainment bias since these individuals are more likely to have had genetic testing before the advent of universal genetic testing for PDAC, when the requirement for personal or family history of other cancers inflated the positive rate. Further research is needed to define factors that impact survival of PV carriers with PDAC, including stage at diagnosis (which could be influenced by high-risk surveillance) and use of targeted therapies. (Table 2) . Respondents with an affected FDR were significantly more likely to report surveillance than those without this history (p \ 0.0001). PDAC risk perception and PDAC cancer worry were not associated with a significantly different rate of PDAC surveillance (p = 0.20 and p = 0.35, respectively).

Conclusions An affected FDR is predictive of higher PDAC risk perception and surveillance; this should be incorporated when counseling at-risk individuals. Additional factors might also contribute to risk perception and surveillance practices but more data are needed, especially among minority populations and individuals with rare genetic syndromes with an elevated PDAC risk. (Fig. 1) . AA patients had significantly lower rates of genetic testing compared to NHW patients (19% vs. 42%, p \ 0.0001) ( Fig. 2A) . P/LPVs were found in 2 (8%) AA patients and 37 (24%) NHW patients (p = 0.10). AA patients had significantly lower rates of documented recommendation for genetic testing (34% vs. 56%, p \ 0.0001) (Fig. 2B) . When recommendation for genetic testing was documented, there was no statistically significant difference in rates of testing between AA and NHW patients (62% vs. 75%, p = 0.08) (Fig. 2C) . Conclusions Genetic testing in PDAC patients is unacceptably low especially among AA patients. The disparity in testing is likely related to lack of provider recommendation more than patient uptake. Lack of testing leads to missed opportunities for potential targeted therapies and improved outcomes as well as identification of at-risk family members who could potentially benefit from screening. Strategies to improve genetic testing in PDAC patients, especially AA patients, are needed to ensure equitable benefits for patients and their family members. (Table 1) . We assessed how the detection of adenomas can mediate the association between colonoscopy screening intervals and CRC. The number of adenomas detected at each screening visit was modeled as a function of the screening interval. Then, the predicted number of adenomas corresponding to the different screening intervals was used as a time-dependent variable in a survival model for CRC.

Results 46 CRCs were found during follow-up and 47.5% of LS patients had at least one adenoma detected either at the first colonoscopy or during follow-up. The mean number of adenomas detected decreases by 1.6 (p = 0.04), 2.5 (p \ 10-3) and 4.8 (p \ 10-3) for a screening interval between 1-2 years, 2-3 years, [ 3 years vs. ? 1 year, respectively, after 10 years follow-up. In turn, a large number of adenomas was associated with a decreased risk of CRC over time with a corresponding hazard ratio of 0.80 [95% CI = 0.66-0.97] (p = 0.02). The cumulative risk of CRC in males and females for different screening intervals (for individuals with adenomas detected) and for individuals without adenomas is represented in Fig. 1 .

Conclusions Shorter intervals between colonoscopies are efficient at detecting and removing adenomas, the precursor of CRC, which in turn reduce CRC risk. Yet, a large proportion of LS patients had no adenomas detected in our study and remained at high risk of CRC.

Columbus, OH, USA 5 Chicago Genetic Consultants, LLC, Northbrook, IL, USA 6 Genome Medical, South San Francisco, CA, USA Background Evidence-based guidelines exist for identifying colorectal cancer patients at risk of having Lynch syndrome (LS) through tumor screening; however, referral rates to genetic counseling after an abnormal tumor screen vary by institution. Gaining an understanding of genetic counselor experiences is needed to increase successful implementation and maintenance of colorectal tumor screening programs.

Methods An online survey was administered to genetic counselors in the United States to explore their experiences with colorectal tumor screening programs. Participants were recruited from the Collaborative Group of the Americas on Inherited Gastrointestinal Cancer, the American Board of Genetic Counseling, the National Society for Genetic Counselors, and the Lynch Syndrome Screening Network.

Participants were asked a series of survey questions regarding referral rates, champions for implementation and maintenance, and ownership of the tumor screening program. Descriptive statistics are reported alongside results of Fisher's Exact Test and Chi-Square test.

Results Of the 78 respondents, around half could provide exact (10.7%) or estimated (37.3%) numbers of patients referred from positive tumor screening. The other half of respondents did not know (13.3%) and could not estimate (38.7%) the number of patient referred due to positive tumor screening.. Nearly half (47.4%) of participants knew of a champion for implementation and 32% knew of a champion for maintenance (Figs. 1, 2) . Less than half of participants (43.6%) knew which specialty had ownership of the tumor screening program. In general, participants who were unsure of champions for implementation and maintenance, or ownership of the program were more likely to not know when the tumor screening program was implemented (p = \ 0.001) and were unable to provide referral rate estimates (p = \ 0.001).

Conclusions It is concerning that many genetic counselors who participated did not know when, who, or what specialty championed the implementation and maintenance or has ownership of the tumor screening program at their institutions. The lack of knowledge found about champions for maintenance and ownership suggests that genetic counselors may have minimal involvement in their tumor screening programs. Lack of knowledge about the number of patients referred to genetics suggests that tumor screening program tracking is often lacking.

Expanding the phenotype: case report of PMS2associated early onset colorectal cancer Background Of the four mismatch repair (MMR) genes, PMS2 variant carriers have the lowest colorectal cancer risk. We collected a prospective cohort to estimate the prevalence of adenomas. As a next step we would like to assess the proportion of adenomas with PMS2deficiency.

Methods Our current cohort consists of 171 PMS2 variant carriers. We recorded the occurrence and characteristics of incident adenomas and CRC. After receiving consent to request clinical data, we obtained information through PALGA, the Dutch nationwide network and registry of histo-and cytopathology, and by requesting colonoscopy reports at gastroenterology departments. We had a pilot cohort of twenty polyps available for immunohistochemical staining of the PMS2 protein.

Results During a total of 675 colonoscopies (1044 observation years, median surveillance interval 2 years), 435 polyps were removed, of which 237 (54.5%) were adenomatous. Forty-one (16.9%) of those adenomas were advanced (i.e. C 1 cm in diameter, villous component and/or high-grade dysplasia). None of the twenty polyps that were immunohistochemically stained showed loss of PMS2 expression, suggesting late involvement of PMS2 deficiency in the pathway to cancer. One incident CRC was reported. Discussion In this large cohort of PMS2 variant carriers, only one incident CRC were observed. This tumor was preceded by a colonoscopy with insufficient bowel preparation. Further analyses are required to investigate the timing of PMS2 deficiency in the development of colorectal cancer, for which we are actively searching for collaborators.

From counseling to registering: Opportunities unveiled in a five-year experience of registering familial cancers in Iran

Massih Bahar

Background Not all developing countries have established familial cancer registries, a task which requires vision and concerted efforts.

Here, we propose that with certain crucial elements in place, clinical cancer genetic counseling settings could undertake the basic tasks of small intra-institutional registries and thus generate the potential for larger, more effective ones. Methods This commentary is based upon our five-year multi-central experience on familial cancer genetic counseling service and registry.

Results To be able to function as a basic registry, we had to add mechanisms for registering and surveillance downstream to genetic counseling and diagnosing. Thus, organizational and workflow designs had to be modified to reflect the additional tasks such as arranging, facilitating and documenting diagnoses and screenings. Among the participating personnel, the coordinator was a key element and the hinge of services of our basic registry. We found the coordinator's dedication and tenacity vital to registry efficiency. Nevertheless, participation of clinicians was an equally important factor in our workflow. In our experience, in order to have access to necessary medical services, counseling settings are best to be located in hospitals with capacity to meet their medical investigation demands. Furthermore, surgery ward was our preferred location. This choice brought a number of advantages including access, sufficient transit time, oriented staff and steady logistical provision. Also, in most cases, a close relative companied the patient and this provided us with better information acquiring, family testing and follow-up planning. Also notably, surgeons were available for possible consideration of management options.

Finally, our participation in multidisciplinary tumor board (MDT) tumor boards made informative sessions with clinicians of various fields possible where we adapted the familial/hereditary cancer guidelines to our local capacities. Likewise, we tried to convey the importance of hereditary/familial approach, a notion we found effective in complementing surgical management with a dimension of precision medicine. We also found that MDT sessions are proper places to select familial/hereditary cases. Conclusions The path from cancer genetic counseling settings to a basic functional registry may differ in each country. Nonetheless, from our standpoint, one could be certain that opportunities greatly outweigh the challenges. screening, prevention, and treatment. However, many barriers to testing exist. We assessed patient barriers to inform content of a patient-facing tailored messaging tool aimed at increasing uptake of genetic testing. Methods A novel online survey was sent to academic medical center patients C18 years old who met criteria for genetic evaluation based on their cancer type and age at diagnosis. Untested participants were asked how true 33 barriers to genetic testing were to them using a 5-point Likert scale (1 = not true at all, 5 = very true). Barrier items encompassed several domains including worry/fear, lack of education, cost, impact of testing, psychosocial distress, genetic discrimination, stigma, religious beliefs, and logistics. Mean value (M) and endorsement score (ES, total percentage of 4's and 5's) were calculated for each item (Table 1) . A readiness score was calculated based on mean response to questions of confidence, importance, and readiness to get genetic testing in the next year (10-point scale). Items with negative correlation to readiness score were counted as true barriers.

Results 138 participants were included in this analysis; the majority were white (86%) and 55% described themselves as male. Items with the highest mean value and ES included worry about family members (M=3.78, ES=71.1%), lack of information on the testing process (M=3.74, ES=70.1%), and lack of information about the value of testing (M=3.64, ES=62.3%). These three items, and four additional items were positively correlated with readiness. 25 items had negative correlation with readiness. Items with the strongest negative correlation were related to genetic testing knowledge including limited utility for cancer prevention (-0.396, p.05), concern with test accuracy (-0.357, p.05), and belief that there is no purpose in testing (-0.352, p.05).

Conclusions Some items commonly reported as barriers with high mean and ES were positively correlated with readiness, suggesting they may be facilitators rather than barriers to testing. Many items with strong negative correlations to readiness were related to knowledge about genetic testing, which may be an effective target for intervention through educational content and tailored counter-messaging. In addition, awareness of barriers to genetic testing is key for healthcare providers to help better facilitate genetic testing discussions with patients. Background Individuals with a pathogenic or likely pathogenic (PLP) CDH1 variant are advised to undergo a risk-reducing total gastrectomy (TG) given elevated risk for hereditary diffuse gastric cancer (HDGC). Annual endoscopic surveillance, an alternative to surgery, may result in detection of occult foci of signet ring (SRCs), a hallmark of early HDGC. We aim to identify factors predictive of detecting SRC foci on biopsy during esophagogastroduodenoscopy (EGD) in patients with CDH1 mutation and to identify the time to detection of SRC during endoscopic surveillance. Methods All patients with a PLP CDH1 mutation were evaluated for the presence/absence of SRC foci on EGD performed from 2013 to 2020. Demographic, endoscopic, and pathology covariates were recorded. Logistic regression analysis identified factors predictive of SRC foci detection on EGD. Time to detection of SRC on surveillance was estimated using Kaplan-Meier method. Results 227 patients with PLP CDH1 mutations were identified. 205 (90.3%) patients underwent [ 1 surveillance EGD. SRC foci were identified in 134 (59%) patients on surveillance EGD; 93 patients (41%) did not have any SRC foci identified. Most patients were Caucasian (95.2%), females (67%), with a mean age of 44.7 ? 14.7 years at time of CDH1 diagnosis. On univariate analysis, younger age at time of CDH1 diagnosis (OR 0.98,95% CI 0.96 -1.00) and elevated body mass index (BMI) (OR 1.05, 95% CI 1.01 -1.10) were associated with increased risk for the presence of SRC foci on biopsy (P=0.03 for both). Younger age and elevated BMI remained predictive for SRC on multivariate analysis (OR 0.97, 95% CI 0.96 -0.99; OR 1.07, 95% CI 1.01 -1.11, respectively, P = 0.01 for both) (Figure 1) . Median time for identification of SRC foci on EGD surveillance was 41 months (Figure 2) . Conclusion From the time of first surveillance endoscopy, our results demonstrate that it takes a median of 41 months on active surveillance before successful detection of SRC foci on endoscopic biopsies. While age and BMI may influence detection, our findings highlight the occult nature of this disease and the viability of surveillance as an alternative to TG. Background CTNNA1 gene mutations are associated with possible increased risk for developing gastric cancer (GC). The International GC Linkage Consortium notes that individuals with CTNNA1 mutations may consider prophylactic total gastrectomy and other cancer prevention measures as recommended for Hereditary Diffuse Gastric Cancer families. These recommendations are currently based on very limited data. Case Presentation A 54-yo female newly diagnosed with multiple primary ipsilateral breast cancers. Her family history is significant for metastatic bone cancer in her mother, brain cancer in her MGF, NHL in her father and endometrial cancer in her paternal aunt. She underwent a large Multi-Gene Panel (MGP) and was initially identified to have a loss-of-function (LOF) pathogenic germline mutation (p.R731*) in the CTNNA1 gene. CTNNA1 recommendations were reviewed with the patient in the context of her reported personal/family history, which are not suggestive of a CTNNA1 mutation. Two months after result disclosure, the laboratory sent the counselor an update noting that an internal retrospective review of cancer paneltested families highlighted that multiple LOF variants were identified in the CTNNA1 gene in families who, similar to this patient, have no reported clinical history of gastric cancer. The rarity with which CTNNA1 LOF alterations are found in gastric cancer cohorts, and the frequency of these variants in unaffected families, lead the laboratory to reclassify LOF alterations in CTNNA1 to variants of unknown significance until more information is available regarding the relationship between mutation type and cancer risk.

Discussion This case was difficult; the patient was focused on her breast cancer treatment, and was not receptive to counseling regarding the initially classified pathogenic result and associated recommendations. While this downgrade was helpful to the patient, it can still be difficult to explain why this reclassification occurred; particularly in a short period of time, and to manage potential patient anxiety that manifested given the initial classification. This case highlights the complexities of counseling for gene mutations for which there is limited data and emphasizes the role of pre-/post-test genetic counseling to accompany MGP testing. Further, it illustrates the intricacies of result reclassification and managing patient/counselor expectation around the interpretation of mutations in newly described genes.

The immune profile of normal colonic mucosa as a possible tumor risk modifier in Lynch syndrome Background Tumors arising in individuals with Lynch syndrome (LS), the most common inherited colorectal cancer (CRC) syndrome, are characterized by the high load of immunogenic frameshift neoantigens and a pronounced immune infiltration. In contrast to the immune milieu of LS CRC, the immune status of normal colorectal mucosa in LS is not well characterized. In this study, we analyzed the immune infiltrate in tumor-distant normal colorectal mucosa from LS CRC patients, sporadic MSI and MSS CRC patients, and cancer-free LS carriers. Methods 215 and 234 FFPE normal colonic mucosa tissue sections, 140 and 124 adenomas, and 24 and 22 LS CRCs, were immunohistochemically stained and quantified for CD3-positive and FOXP3positive T cells, respectively. In addition, CD3-positive T cells were quantified in an independent cohort of 97 FFPE normal rectal mucosa tissue sections from LS carriers enrolled in the CAPP2 clinical trial. Gene expression profiling using the NanoString nCounter platform covering 770 immune-relevant genes was performed in a subset of samples.

Results Significantly elevated CD3-positive and FOXP3-positive T cell densities were observed in the normal mucosa of LS individuals compared to non-MSI controls. Distinct immune profiles in the colonic mucosa of LS carriers with and without tumor manifestation were revealed by the gene expression and cluster analysis. The mucosa of cancer-free LS carriers was particularly characterized by an overrepresentation of CD45-positive, exhausted CD8-positive, NK, Mast and B cell populations. In comparison to normal mucosa of both LS cancer patients and cancer-free LS carriers, LS tumor tissue showed overrepresentation of regulatory T cells and neutrophils. A long-term follow-up of LS carriers within the CAPP2 trial showed a correlation between mucosal T cell infiltrate and time to subsequent tumor occurrence. Conclusions Our observations suggest that LS carriers present with an altered mucosal immune environment even in the absence of manifest cancer and support the hypothesis that the immune profile in the colorectal mucosa may be a temporary or permanent tumor risk modifier in LS carriers.

Publisher's Note Springer Nature remains neutral with regard to jurisdictional claims in published maps and institutional affiliations.

National Comprehensive Cancer Network. Genetic/Familial High-Risk Assessment: Colorectal (Version 1

National Comprehensive Cancer Network

A clinical guide to hereditary cancer panel testing: evaluation of gene-specific cancer associations and sensitivity of genetic testing criteria in a cohort of 165,000 high-risk patients

Patients Tested at a Laboratory for Hereditary Cancer Syndromes Show an Overlap for Multiple Syndromes in Their Personal and Familial Cancer Histories

disclose that I am a part-time employee of InheRET Inc, receiving salary. in the NCI Li-Fraumeni syndrome study

Increased risk of colorectal adenocarcinoma (CRC) and other gastrointestinal (GI) cancers in LFS has led to screening recommendations of colonoscopy and endoscopy starting at age 25 years. However, understanding of the spectrum of GI neoplasms in LFS is limited. Methods This study evaluated 510 individuals with germline TP53 pathogenic or likely pathogenic (P/LP) variants. High-grade dysplasia (HGD) was included with the respective site malignancy. LFS-associated cancer incidences were compared with the Surveillance

Twelve of the 26 CRC/HGD were identified prior to age 40, including two before age 25 years. Esophageal and gastric cancer/HGD were diagnosed in four (0.8%) and 11 (2.2%) individuals respectively, at median ages of 49 (range 34-62) and 54 (range 32-70) years. Other lower GI tract neoplasms included nonepithelial malignancies in five (1.0%) and benign polyps in 73 (14.3%) individuals. Other upper GI tract neoplasms consisted of small intestine lymphoma in one (0.2%) and benign polyps in 11 (2.2%) individuals. Solid GI organ findings included pancreatic cancer in nine (1.8%), liver carcinoma in three (0.6%), liver sarcomas in three (0.6%), and benign liver tumors in four (0.8%) individuals. We observed increased incidence and

3% (3.5-15.1%), respectively, by age 70. Conclusions Our study highlights the increased burden of GI malignancies in individuals with P/LP germline TP53 variants compared with the general population and reinforces the importance of existing high-risk surveillance for GI cancers

MLH1 promoter hypermethylation: are you absolutely sure about the absence of MLH1 germline mutation? About a new case

Coexisting somatic promoter hypermethylation and pathogenic MLH1 germline mutation in Lynch syndrome

Genetic and epigenetic modification of MLH1 accounts for a major share of microsatellite-unstable colorectal cancers

Tumour MLH1 promoter region methylation testing is an effective prescreen for Lynch Syndrome (HNPCC)

Lynch syndrome-associated endometrial carcinoma with MLH1 germline mutation and MLH1 promoter hypermethylation: a case report and literature review

Null pattern'' of immunoreactivity in a Lynch syndrome-associated colon cancer due to germline MSH2 mutation and somatic MLH1 hypermethylation

MLH1 promotor hypermethylation does not rule out a diagnosis of Lynch syndrome: a case report

Universal screening for Lynch syndrome in endometrial cancers: frequency of germline mutations and identification of patients with Lynch-like syndrome

Patients with an unexplained microsatellite instable tumour have a low risk of familial cancer

USA Referrals to genetic counseling due to abnormal tumor screening for lynch syndrome: impact of champions

Genetic counseling program in familial breast cancer: analysis of its effectiveness, cost and cost-effectiveness ratio

Family history-based colorectal cancer screening in Australia: A modelling study of the costs, benefits, and harms of different participation scenarios

Across Culture and Health Systems: Argentina